Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immunobiome Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being processed by 1 distinct examiner in 1 distinct art unit. RAHMAN, MASUDUR is the busiest examiner, currently handling the 1 pending office action for the company.
The prosecution profile is focused on a single pending office action, which constitutes the company's current active filings. The involvement of 1 distinct examiner and 1 distinct art unit indicates a singular path for the Biotechnology & Pharmaceuticals portfolio. Practitioners should focus on the specific examination style of RAHMAN, MASUDUR to advance the pending office action.
Because the 1 pending office action represents the entire active workload, its resolution is the primary focus for the company's patent strategy. Practitioners should ensure that all technical arguments are precisely aligned with the standards of the Biotechnology & Pharmaceuticals area. Successfully navigating the 1 distinct examiner's review will be critical for maintaining the momentum of the company's intellectual property development.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292945 | METHOD FOR PRODUCING A SPONTANEOUS METASTASIS MODEL | RAHMAN, MASUDUR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292945 | METHOD FOR PRODUCING A SPONTANEOUS METASTASIS MODEL | RAHMAN, MASUDUR | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292945 | METHOD FOR PRODUCING A SPONTANEOUS METASTASIS MODEL | RAHMAN, MASUDUR | 1633 | §102§103§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunobiome Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Masudur Rahman has the most, with 1 of Immunobiome Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
